Advertisement
Skip to Content
Morningstar

Hartford Healthcare R3 HGHRX

Morningstar Analyst Rating
Analyst rating as of | See Hartford Funds Investment Hub
  • NAV / 1-Day Return 35.43  /  0.87 %
  • Total Assets 1.3 Bil
  • Adj. Expense Ratio
    1.610%
  • Expense Ratio 1.590%
  • Distribution Fee Level Above Average
  • Share Class Type Retirement, Medium
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.00
  • Turnover 33%

USD | NAV as of Feb 06, 2023 | 1-Day Return as of Feb 06, 2023, 11:32 PM GMT+00:00

Morningstar’s Analysis HGHRX

Will HGHRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Process Pillar

The Process Pillar is our assessment of how sensible, clearly defined, and repeatable HGHRX’s performance objective and investment process is for both security selection and portfolio construction.

People Pillar

The People Pillar is our evaluation of the HGHRX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

Parent Pillar

The Parent Pillar is our rating of HGHRX’s parent organization’s priorities and whether they’re in line with investors’ interests.

A promising new era.

Analyst

Summary

| by Andrew Redden

New comanagers are well equipped to execute Hartford Healthcare’s proven approach. Its Morningstar Analyst Rating remains Silver or Bronze, depending on share class fees.

Unlock our full analysis with Morningstar Investor